Trial Profile

A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tarloxotinib (Primary)
Indications Non-small cell lung cancer
Focus Proof of concept; Therapeutic Use
Acronyms TH-4000
Sponsors Rain Oncology

Most Recent Events

29 Dec 2022 According to Rain Oncology media release, Rain Therapeutics has changed its name to Rain Oncology.
29 Sep 2016 Status changed from recruiting to discontinued, considering the the totality of the clinical data obtained in the interim analysis which do not justify further evaluation, according to a Threshold Pharmaceuticals media release.
29 Sep 2016 Interim Results published in a Threshold Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com